Feed GREH
Summary
48 / 100 · Bulios Score
Valuation 100Growth -Profitability 40Quality 22Debt 38Stability 37
What speaks for it
- Out of every 100 USD of revenue, 378 USD is left as net profit.
- You pay 0.3 USD for 1 USD of yearly profit, little for its sector.
What to watch
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapP/E today 0.3
Drug Manufacturers - Specialty & Generic industry median
Today you pay 0.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
20202021202220232024
Diluted EPS (USD)
20202021202220232024
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 4.3 USD
- Sales and administration 411 USD
- Taxes and other -697 USD
- Net profit 378 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 378 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $556.0
Debt $3.03M
Free cash flow over 12 months -$1.04M
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.